Replies to post #149624 on Biotech Values

[DewDiligence]

However, for an investor who buys based on a faulty inference, the downside might be quite real and quite unpleasant… this is a tricky one.

I see nothing tricky about it provided you have the buying power to add shares without going on margin. As noted in #msg-79983003, I’m very comfortable buying at the current price even if, as is likely, the 10b5-1 hiatus turns out to be nothing. Thus, adding some shares based on the 10b5-1 inference is essentially a free shot, IMO.